At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, Carboplatin, and 1 other intervention for Ovarian Cancer. Completed, enrolled 29 participants across 2 sites.
Detailed Summary
Phase II single arm, open label, nonrandomized study. The aim of our study is to assess the Progression Free Survival (PFS) in suboptimally cytoreduced epithelial ovarian/ primary peritoneal/ fallopian tube cancer patients treated with the novel combination of carboplatin every 21 days (triweekly) /weekly paclitaxel IV with pembrolizumab IV followed by maintenance pembrolizumab IV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsThe Cleveland Clinic, Merck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartOct 2016
Primary CompletionMay 2022
Study CompletionDec 2023
TodayJul 2026
First PostedMay 10, 2016
Enrollment StartOct 1, 2016
Primary CompletionMay 1, 2022
Study CompletionDec 30, 2023
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 10.1 years ago
Interventions
Pembrolizumabdrug
IV every 21 days at 200 mg
Carboplatindrug
IV every 21 days
Paclitaxeldrug
IV infusion (80mg/m2) every 7 days for 6 cycles